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Introduction
The metabolic syndrome (MetS) is characterised by
an array of cardiovascular risk factors which may be
predictive of longer-term disease consequences in
certain individuals. The syndrome is associated with
insulin resistance and hyperglycaemia, and is associ-
ated with an increased risk of developing type 2 dia-
betes and cardiovascular disease (1,2). The
prevalence of MetS is rising in Western countries
because of a progressive increase in the proportion
of patients with diabetes and obesity (3).
The hypertensive population with MetS represents
a particularly high-risk group because of the
increased incidence of cardiovascular complications
(4–8). In fact, current European Guidelines have
included the MetS as an important component of
the risk stratiﬁcation in patients with hypertension,
as it markedly increases cardiovascular risk (8).
Blood pressure (BP) control is essential in this popu-
lation to improve prognosis. But, only a small pro-
portion of hypertensive patients with MetS attain BP
goals (9). The poor treatment compliance may in
part explain this poor BP control. One of the most
important reasons for this inadequate compliance is
the presence of adverse events related to antihyper-
tensive therapy. This is particularly important in
these patients, moreover, taking into account that
they usually need several drugs to achieve BP objec-
tives, that increases the possibility of causing side
effects (9,10).
Calcium channel blockers (CCB) are drugs widely
used for the treatment of hypertension. Lercanidipine
is a highly lipohilic third generation dihydropyridine
(DHP) (11). Its efﬁcacy has been evaluated in non-
comparative (12–16) and comparative studies (17–
19). Lercanidipine is generally well tolerated during
monotherapy in patients with mild-to-moderate
hypertension even when compared with other DHPs
(12,14,20). Nonetheless, this information is generally
provided by clinical trials with commonly strict
selection criteria with less information available from
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the tolerability of high doses of lercanidipine with amlodipine and nifedipine
gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily
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group of patients with metabolic syndrome (MetS). Results: Three hundred and
thirty-seven of the 650 study population fulﬁlled criteria of MetS, 233 (69.1%) on
lercanidipine and 104 (30.9%) on amlodipine⁄nifedipine GITS. Overall, a signiﬁ-
cantly lower proportion of lercanidipine-treated patients showed adverse reactions
(ARs) when compared with patients receiving other-dihydropyridines (DHPs) (60.1%
vs. 73.1%, p = 0.003). Similarly, the most common vasodilation-related ARs
(oedema, swelling, ﬂushing and headache) were signiﬁcantly less frequent in ler-
canidipine group (all p < 0.01). Conclusion: In conclusion, lercanidipine appears
to exhibit a better tolerability proﬁle and less vasodilation-related ARs compared
with other DHPs in hypertensive patients with MetS.
What’s known
Only a small proportion of hypertensive patients
with MetS attain BP goals. The poor treatment
compliance may in part explain this poor BP
control. One of the most important reasons for this
inadequate compliance is the presence of adverse
events related to antihypertensive therapy. CCB are
drugs widely used for the treatment of
hypertension. However, tolerability of different CCB
may differ, especially in those patients at high risk,
such as those with MetS.
What’s new
In a large sample of hypertensive patients with
metabolic syndrome recruited and managed in
conditions of daily practice, this study shows that
treatment with lercanidipine at high doses is
associated with a lower rate of adverse events
related to vasodilation compared with high doses
of amlodipine or nifedipine GITS.
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starting dose was 10 mg qd, scarce data were avail-
able with higher doses. Although lercanidipine has
been compared with other antihypertensive drugs in
high-risk populations such as elderly people, diabet-
ics and patients with renal impairment, to date there
is no information about the tolerability and efﬁcacy
of this drug in hypertensive subjects with MetS in
daily clinical practice (19–21).
The TOlerabilidad de LERcanidipino 20 mg frente
a Amlodipino y Nifedipino en CondicionEs normales
de uso (TOLERANCE) study was aimed to compare
the tolerability, with special emphasis on vasodila-
tion-related adverse reactions (ARs), of high doses of
lercanidipine with other DHP (amlodipine and
nifedipine GITS) also given at daily high doses in
conditions of common clinical practice (22). In this
paper, we present the data related to the subgroup of
patients with MetS from the TOLERANCE study
database.
Patients and methods
The TOLERANCE was an observational, cross-sec-
tional and multicentre study performed in Primary
Care Centres from all around Spain. Outpatients
aged ‡ 18 years, of both genders, with essential
hypertension who had been treated at least for
1 month with lercanidipine, amlodipine or nifedipine
GITS at low doses (10, 5 and 30 mg daily respec-
tively) and who were titrated to higher doses of the
same drugs (20, 10 and 60 mg respectively) because
of an uncontrolled BP in a 2 : 1 design were
included (22). The choice of the CCB was based on
the physicians’ decision, according to their own clini-
cal criteria.
Blood pressure readings were taken with a mer-
cury sphygmomanometer or validated automatic
devices where available with the patient in a seated
position and the back supported, and after resting
5 min. Two measurements were taken by physicians
following the current guidelines and the mean was
recorded (8). Adequate BP control was deﬁned as
systolic BP < 140 mmHg and diastolic BP <
90 mmHg (< 130 and < 80 mmHg for diabetics)
(23). As this study was aimed to reﬂect clinical
practice, when BP control was not attained after ler-
canidipine, amlodipine or nifedipine GITS at high
doses, the investigators could freely add more antihy-
pertensive medication. Patients underwent a com-
plete physical examination, and they should have a
complete blood test (haematology and biochemistry
with a lipid proﬁle) performed within the last
3 months. Waist circumference was measured at the
midway point between the iliac crest and the costal
margin. MetS was diagnosed according to NCEP-
ATP III criteria, requiring the presence of three or
more of the following: abdominal obesity (waist cir-
cumference > 102⁄88 cm or > 40⁄35 inches for
men⁄women); triglycerides ‡ 150 mg⁄dl; high-
density lipoprotein cholesterol < 40⁄50 mg⁄dl (men⁄
women); fasting glucose ‡ 110 mg⁄dl or BP
‡ 130⁄85 mmHg (24).
Adverse reactions were spontaneously reported by
the patient or elicited using a 16-item checklist simi-
lar to the one used in the COHORT trial (20)
including those symptoms considered related to
vasodilation and the most commonly adverse events
reported during registration trials. The study was
conducted according to good clinical practice guide-
lines and was approved by the local Clinical Research
Ethic Committee. All participants provided a written
informed consent to take part in the study.
Statistical analysis
The primary variable of the study was evaluated
through the frequency of ankle oedema and other
vasodilation-related adverse events according to the
questionnaire used in the study. Secondary end-
points were frequency of spontaneously adverse
events notiﬁed by the patient, rates of BP control
and percentage of patients classiﬁed as good compli-
ers according to the Haynes–Sacket test (25). Contin-
uous variables were averaged and expressed as
means ± standard deviation. Categorical items were
expressed as per cent frequency; 95% conﬁdence
intervals were provided when necessary. Differences
between means of different parameters were com-
pared by the Student t-test. Differences between per-
centages were compared with the chi-squared test.
Categorical data were also analysed with this test.
p < 0.05 was used as the level of statistical signiﬁ-
cance. A logistic regression analysis was performed to
determine what factors could inﬂuence the incidence
of adverse events related to vasodilation (dependent
variable). Clinical characteristics of study population,
cardiovascular risk factors, target organ damage,
associated clinical conditions, antihypertensive treat-
ments, concomitant treatments and biochemical
parameters were included as independent variables in
the logistic regression analysis.
Results
A total of 61 investigators recruited 650 patients
(67.4 ± 11.1 years; 47% male) in the overall TOLER-
ANCE study. A total of 337 patients (52%) of the
study population fulﬁlled criteria of MetS, of
whom 233 (69.1%) were taking lercanidipine and
104 (30.9%) amlodipine⁄nifedipine GITS. Clinical
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both groups, although there was a trend to more
diabetes and more obesity (p = 0.13 and p = 0.26
respectively) in lercanidipine group (Table 1).
The changes in BP and heart rate along the study
are shown in Table 2. There was a signiﬁcant decrease
of BP values between high- and low-dose treatment in
each group, but without differences between both
groups. The percentage of patients with an adequate
BP control was 41.4% in the lercanidipine group and
35.0% in the amlodipine⁄nifedipine group (p = ns).
The proportion and type of concomitant antihyper-
tensive drugs were similar in both groups (46.4% in
lercanidipine group needed additional antihyperten-
sive to achieve BP goal vs. 53.9% in amlodipine⁄nifed-
ipine GITS group, p = ns) (Table 3). There were no
signiﬁcant differences between both groups in bio-
chemical parameters.
With regard to the side effects reported by the
questionnaire at high doses, patients treated with ler-
canidipine showed a lower proportion when com-
pared with amlodipine⁄nifedipine GITS group
(60.1% vs. 73.1%, respectively, p = 0.003). Similarly,
lercanidipine vs amlodipine⁄nifedipine GITS showed
a better tolerability proﬁle at low doses (39.9% vs.
54.8%, respectively, p = 0.02). Table 4 shows the dis-
tribution between groups of drug-related signs and
symptoms according to the checklist. The most fre-
quent adverse event was ankle oedema in both
groups. Almost all side effects were more prevalent
in amlodipine⁄nifedipine GITS group. The Figure 1
shows the risk reduction for the most frequent vaso-
dilatation-related adverse events. The classiﬁcation of
the severity of ARs is shown in Table 5. According
to the Haynes–Sackett test, the percentage of patients
considered as good compliers was similar in both
groups (93.7% lercanidipine vs. 92.7% in amlodi-
pine⁄nifedipine, p = ns). Concerning the changes in
antihypertensive treatment made by the investigators,
in 91.5% of patients in the lercanidipine group the
treatment was maintained, whereas in the amlodi-
pine⁄nifedipine group only 55.9% did not changed
their treatment regimen (p < 0.001).
A logistic regression analysis was performed to
examine which factors could inﬂuence the appear-
ance of adverse events related to vasodilatation. The
use of diuretics and the history of cardiac disease
were related to the presence of side effects [odds
ratio 2.93, 95% CI: 1.29–6.65 and 8.20 (2.45–27.43)
Table 1 Clinical characteristics of study population
Lercanidipine
Amlodipine⁄
nifedipine p
Age (years) 65.1 ± 11 66.1 ± 10 ns
Gender (female) 57.3% 58.7% ns
Diabetes 43.2% 33.7% ns
Hypercholesterolaemia 58.5% 60.4% ns
Sedentary life style 72.7% 75.0% ns
Obesity (BMI ‡ 30 kg⁄m
2) 63.3% 56.6% ns
History of heart disease 61.8% 62.4% ns
Time of evolution of
hypertension (months)
68.8 ± 14 70.7 ± 15 ns
Data were expressed as mean ± standard deviation or percent-
ages. ns, not signiﬁcant (p > 0.05); BMI, body mass index.
Table 2 Blood pressure and heart rate along the study
Low dose High dose
Lercanidipine Amlodipine⁄nifedipine p* Lercanidipine Amlodipine⁄nifedipine p p
SBP 157.9 ± 14.0 157.8 ± 10.4 ns 144.4 ± 12.9 145.0 ± 11.4 ns < 0.05
DBP 92.7 ± 6.7 92.4 ± 7.3 ns 83.3 ± 6.4 84.5 ± 7.1 ns < 0.05
HR 78.7 ± 8.2 78.5 ± 7.1 ns 77.1 ± 7.6 77.2 ± 7.8 ns ns
*p between lercanidipine and amlodipine⁄nifedipine groups at low dose. p between lercanidipine and amlodipine⁄nifedipine groups
at high dose. p between high vs. low dose. SBP, systolic blood pressure (mmHg); DBP, diastolic blood pressure (mmHg); HR, heart
rate (bpm); ns, not signiﬁcant.
Table 3 Concomitant antihypertensive therapy
Drugs
Lercanidipine
(%)
Amlodipine⁄
nifedipine (%) p
Diuretics 24.0 23.1 ns
ARB 16.3 20.2 ns
ACE inhibitors 11.6 17.3 ns
Beta blockers 5.2 7.7 ns
Alpha blockers 3.4 3.9 ns
Others 0.9 1.0 ns
ARB, angiotensin receptor blockers; ACE, angiotensin-convert-
ing enzyme; ns, not signiﬁcant.
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lower proportion of ARs [0.44 (0.23–0.85)].
Discussion
metabolic syndrome is very common in hypertensive
population. It has been estimated a prevalence of
about 20% in general population and approximately
a half in hypertensives, accordingly with our data
(4,9,26). This is not surprising, taking into account
that the majority of patients with hypertension com-
monly attended in general practice belong to the car-
diovascular high- or very high-risk groups (27).
Current European Guidelines establish that an
aggressive approach in high-risk hypertensive
patients such as those with MetS is mandatory (8).
Thus, whether the main purpose in the treatment of
hypertension is to achieve an adequate BP control
and to reduce the global cardiovascular risk of the
hypertensive patient, this is critical in hypertensive
patients with MetS (8). Previous studies have shown
that BP control is more difﬁcult to achieve, and only
about 15% of hypertensive patients with MetS daily
attended in Spain are well controlled (9,28). How-
ever, our data showed a marked improvement in
these ﬁgures, with more than 30% of the patients
attaining BP goals, especially in lercanidipine group.
This is not surprising, as it has been recognised that
BP control in Spain has signiﬁcantly improved in the
last years (29).
The efﬁcacy of an antihypertensive drug does not
only depend on the capacity to reduce BP values, but
on its tolerability proﬁle as well. If a drug is well tol-
erated, treatment compliance will raise, and second-
arily improve BP control (30). While randomised
clinical trials are very important to benchmark the
effectiveness and tolerability of therapeutic interven-
tions in a controlled scientiﬁc manner, they do not
Table 4 Distribution of signs and symptoms according to the checklist with dihydropyridines given at high doses
Signs⁄symptoms Global (%) Lercanidipine (%)
Amlodipine⁄
nifedipine (%) p
Ankle oedema 46.9 42.9 55.8 0.007
Flushes 33.8 28.3 46.2 < 0.001
Headache 32.0 27.5 42.3 0.002
Swelling 30.9 25.8 42.3 < 0.001
Fatigue 19.3 15.9 26.9 0.01
Dizziness 16.0 14.2 20.2 ns
Palpitations 14.2 10.7 22.1 0.006
Constipation⁄diarrhoea 13.9 10.3 22.1 0.005
Pyrosis 11.3 8.6 17.3 0.02
Sexual dysfunction 10.4 8.2 15.4 0.04
Dyspnoea 9.8 7.7 14.4 ns
Blurred vision 9.2 8.2 11.5 ns
Skin rush 8.0 4.7 15.4 0.001
Thoracic pain 5.3 6.0 3.8 ns
Gum swelling 2.4 1.7 3.8 ns
Thoracic swelling 1.8 1.3 2.9 ns
ns, not signiﬁcant (p > 0.05).
55.8%
42.9% 42.3%
25.8%
46.2%
28.3%
42.3%
27.5%
0%
20%
40%
60%
80%
100%
Oedema
All p < 0.01
Swelling Flushing Headache
Amlodipine/Nifedipine
Lercanidipine
RRR = 35% RRR = 38.7% RRR = 39%
RRR = 23.1%
Figure 1 Risk reduction for the most frequent
vasodilatation-related adverse events
Table 5 Distribution of severity of adverse events
according to antihypertensive therapy
Severity of
adverse events Lercanidipine
Amlodipine⁄
nifedipine p
Mild (%) 72.9 56.6 0.03
Moderate (%) 25.0 40.8 0.04
Severe (%) 2.1 2.6 ns
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practice (31,32). This study was designed in condi-
tions of common clinical practice.
Dihydropyridines have shown to be effective anti-
hypertensive drugs in several clinical trials, but its
use has been sometimes limited because of their side
effects. The most important adverse events being
those related to vasodilatation, especially ankle
oedema. However, not all the DHPs have the same
tolerability proﬁle. Lercanidipine is a highly lipohilic
third generation DHP (11). Its antihypertensive effect
results from peripheral vasodilatation and decreased
total peripheral resistance (33). This drug has a slow
onset of action that helps to avoid reﬂex tachycardia
associated with other DHP. Our data show that inci-
dence and severity of these side effects is signiﬁcantly
higher in the amlodipine⁄nifedipine group compared
with lercanidipine. As BP reductions and concomi-
tant antihypertensive therapy were similar in both
groups, this difference in the proportion of adverse
events between groups should be explained for a bet-
ter tolerability proﬁle of lercanidipine. For every
group, the increase of dose was associated with a
higher incidence of signs and symptoms related to
vasodilation suggesting that these side effects are
dose dependent. Vasodilatory oedema related to
DHP is probably because of an increase in intracapil-
lary hydrostatic pressure that causes ﬂuid ﬁltration
from the vascular space to the interstitium. It has
been related to an arteriolar dilation that, as a conse-
quence of reﬂex sympathetic activation, is not
accompanied by adequate postcapillary vasodilation
(34,35). On the other hand, lercanidipine has shown
different effects on plasma norepinephrine levels and
a lower sympathetic activation compared with other
DHP (36,37), that could, at least in part, explain the
lower rate of ankle oedema observed with this drug
when compared with amlodipine and nifedipine.
However, the incidence of ankle oedema was high
in both groups (42.9% in lercanidipine vs. 55.8% in
amlodipine⁄nifedipine group) and superior to other
published data in general hypertensive population
(14,20). This is not surprising, taking into account
that patients with MetS are polymedicated that sig-
niﬁcantly increases the risk of presenting side effects
(8). Moreover, it is noticeable that the presence of
ankle oedema was elicited by using the symptom and
signs check list. Thus, it is most likely that a simple
heaviness could be interpreted by the patient as ankle
oedema that could explain the high incidence,
although mild, of that side effect in both groups. On
the other hand, when other studies have used the
same technique to assess the presence of side effects,
the proportion of ARs was very similar (20). In fact,
equivalent risk reductions of ankle oedema have been
found in other studies when compared lercanidipine
with other DHPs (20,38).
In the multivariant analysis, predictors of higher
side effects rates were the use of diuretics, that it is
not unexpected, as oedemas are commonly treated
with diuretics, and the history of cardiac disease,
probably because of the intrinsic higher risk of some
heart diseases for the development of ankle oedema.
Treatment with lercanidipine was a protective factor
compared with the use of amlodipine or nifedipine
GITS.
This is an observational study with the character-
istic design and result limitations of these studies.
This methodology reduces the level of control that
can be exercised to reduce variation and bias (e.g.
random sampling). However, the number of
patients included and the nature of the end-points
being measured minimises this theoretical limita-
tion. The information derived from this kind of
studies aimed to reﬂect the ‘real world’ of clinical
practice appears to be very useful and complemen-
tary to the one obtained from the randomised con-
trolled trials. Observational studies include more
often older patients with a higher comorbidity that,
in terms of drug tolerability, could reﬂect the ‘real
world’ clinical scenario better than randomised
controlled trials. The method used to evaluate com-
pliance is the self-communicated interview as indi-
cated by Haynes–Sackett test. Despite its known
limitations, it has been shown that this test can
determine adequately the treatment compliance in
clinical practice (25,39).
In conclusion, lercanidipine appears to exhibit a
better tolerability proﬁle and less vasodilation-related
ARs compared with other DHPs in hypertensive
patients with MetS.
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